The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
Open accessAbstract
BACKGROUND: We report a case of severe bilateral panuveitis during melanoma therapy with a combination of Dabrafenib, a B-raf (BRAF) inhibitor, and Trametinib, a mitogen/extracellular signal-regulated kinase (MEK) inhibitor. Both of these drugs are effectors in the mitogen-activated protein kinase (MAPK) pathway, which plays an important role in the physiopathology of melanoma. Dabrafenib and Trametinib have shown improved survival of patients with metastatic melanoma but they have also been associated with the development of uveitis. FINDINGS: Our patient was a 55-year-old woman with metastatic melanoma who presented with sudden onset of bilateral painless visual loss. She had been treated with Dabrafenib and Trametinib. Trametinib was discontinued at the onset of symptoms but there was no improvement. Ophthalmological examination revealed severe bilateral non-granulomatous panuveitis, with choroidal thickening, chorio-retinal folds, and multiple serous retinal detachments (SRDs). Topical corticosteroid treatment was initiated, and Dabrafenib was discontinued. A good response was obtained with a recovery of visual acuity of 20/25 on both eyes and an almost complete resolution of the SRDs. CONCLUSIONS: This case highly suggests that MAPK pathway inhibition can lead to severe uveitis. Dabrafenib and Trametinib could have both played a role in inducing the disease. Further studies are needed to evaluate the possible role of the combination of these drugs in inducing uveitis and SRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Apart from p38, inhibitors of other MAPKs, when used in the context of cancer treatment, were shown to have severe uveitis as a side effect, which, although transient and manageable, must be taken into consideration when treating patients [ 192 , 193 , 194 , 195 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [194]
The cited source says what the claim attributes to it.
In the citing paper
“severe bilateral panuveitis during a combined Dabrafenib + Trametinib treatment has been separately reported on multiple occasions [ 194 , 226 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [194]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 1×
“There are several drugs for which the clinical experience is sufficient to establish a “definite,” “probable,” or “possible” association with uveitis using an algorithm proposed by Naranjo and associates [9].”
MethodImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Dabrafenib and its potential for the treatment of metastatic melanoma
Murali, R., Menzies, A. M., & Long, G. V. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s38998 · Cited by 192
Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
Choe, C. H., McArthur, G. A., Caro, I., Kempen, J. H., & Amaravadi, R. K. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.003 · Cited by 113
London, N. J. S., Garg, S. J., Moorthy, R. S., & Cunningham, E. T. (2013) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/1869-5760-3-43 · Cited by 97
McCannel, T. A., Chmielowski, B., Finn, R. S., Goldman, J., Ribas, A., Wainberg, Z. A., & McCannel, C. A. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.976 · Cited by 90
Uveitis in Patients With Late-Stage Cutaneous Melanoma Treated With Vemurafenib
Guedj, M., Quéant, A., Funck‐Brentano, E., Kramkimel, N., Lellouch, J., Monnet, D., Longvert, C., Gantzer, A., & Brézin, A. P. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.3024 · Cited by 58
Schoenberger, S. D., & Kim, S. J. (2013) · Case Reports in Ophthalmological Medicine · doi:10.1155/2013/673796 · Cited by 46 · cited 1×
“The occurrence of serous retinal detachments (SRDs), once associated with moderate anterior uveitis, has been reported in Trametinib therapy [7,8].”
BackgroundUveitis as a Result of MAP Kinase Pathway Inhibition
Joshi, L., Karydis, A., Gemenetzi, M. K., Shao, E. H., & Taylor, S. R. J. (2013) · Case Reports in Ophthalmology · doi:10.1159/000357060 · Cited by 43
Cited by
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Cabanillas, M. E., Ryder, M., & Jimenez, C. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00007 · Cited by 335
DAUD, A. I., & Tsai, K. K. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0456 · Cited by 97
Fujimura, T., Kambayashi, Y., Tanita, K., Sato, Y., Hidaka, T., Otsuka, A., Tanaka, H., Furudate, S., Hashimoto, A., & Aiba, S. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14273 · Cited by 86
Moorthy, R. S., Moorthy, M. S., & Cunningham, E. T. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000530 · Cited by 86
Checkpoint inhibitor-induced uveitis: a case series
Conrady, C. D., Larochelle, M. B., Pecen, P. E., Palestine, A. G., Shakoor, A., & Singh, A. P. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3835-2 · Cited by 76
Metadata
- Authors
- Draganova, D., Kerger, J., Caspers, L., & Willermain, F.
- Affiliations
- Centre Hospitalier Universitaire de Saint-Pierre (BE)
- Institut Jules Bordet (BE)
- Corresponding author
- Draganova, Dafina
- Venue
- Journal of Ophthalmic Inflammation and Infection
- Published
- 2015-06-09
- Volume
- 5
- Issue
- 1
- Pages
- 17-17
- ISSN
- 1869-5760 (ISSN-L)
- PMC
- PMC4460117
- OpenAlex
- W1828732496
- Cited by
- 62
- References
- 10
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 12 · 2020: 6 · 2019: 7 · 2018: 6 · 2017: 6 · 2016: 5 · 2015: 1
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Ophthalmic Inflammation and Infection (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Keywords
- panuveitis, uveitis, melanoma, dabrafenib, trametinib, BRAF inhibitors, MEK inhibitors, MAPK inhibition, drug-induced uveitis, serous retinal detachment, choroidal thickening, metastatic melanoma, topical corticosteroids, vision loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. https://app.cochat.ai/papers/10.1186/s12348-015-0049-9
- The paper
- Draganova, D., Kerger, J., Caspers, L., & Willermain, F. (2015). Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. Journal of Ophthalmic Inflammation and Infection. https://doi.org/10.1186/s12348-015-0049-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.